Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:29 2024-04-15 am EDT			5-day change	1st Jan Change
225.1 ^CHF	+0.04%		+2.41%	-7.93%

Apr. 15	ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating	ZD
Apr. 15	Roche: positive phase III data in lymphoma	CF

ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating

June 07, 2022 at 05:41 am EDT

In his latest research note, analyst Emmanuel Papadakis confirms his recommendation. The broker Deutsche Bank is keeping its Neutral rating. The target price is unchanged at CHF 350.

Latest news about Roche Holding AG

ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating	Apr. 15	ZD
Roche: positive phase III data in lymphoma	Apr. 15	CF
Roche's Late-stage Trial for Columvi Antibody Meets Primary Survival Endpoint in B-cell Lymphoma	Apr. 15	MT
Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial	Apr. 15	DJ
ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating	Apr. 12	ZD
Swiss Market Index Falls as ECB Signals June Rate Cut	Apr. 11	MT
ROCHE HOLDINGS AG : Berenberg reiterates its Neutral rating	Apr. 11	ZD
Roche: designation for Alzheimer's test	Apr. 11	CF
Roche, Eli Lilly Alzheimer's Blood Test to Get Expedited FDA Review	Apr. 11	DJ
Roche, Eli Lilly's Elecsys Blood Test Secures US FDA's Breakthrough Device Designation	Apr. 11	MT
Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis	Apr. 11	CI
Swiss Market Index Little Changed; Barry Callebaut Shines on Revenue Jump	Apr. 10	MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	Apr. 10	MT
Roche: CE mark for Enhertu companion test	Apr. 10	CF
Novartis to cut 680 jobs in product development	Apr. 09	RE
ROCHE HOLDINGS AG : UBS reiterates its Neutral rating	Apr. 09	ZD
ROCHE HOLDINGS AG : Barclays gives a Neutral rating	Apr. 08	ZD
Roche: positive phase II data in hypertension	Apr. 08	CF
Roche's Hypertension Drug Meets Primary Endpoint of Reduced Systolic Blood Pressure in Mid-stage Trial	Apr. 08	MT
ROCHE HOLDINGS AG : Receives a Sell rating from JP Morgan	Apr. 05	ZD
ROCHE HOLDINGS AG : Gets a Sell rating from JP Morgan	Apr. 02	ZD
Global markets live: Apple, UBS, Microstrategy, Merck, Amazon...	Mar. 27
Roche's Chugai Wins Japanese Approval for Piasky Injection	Mar. 27	MT
Roche Obtains US FDA Approval for Cobas Malaria Test	Mar. 27	MT
Roche Gets FDA Approval for Malaria Screen Test	Mar. 26	DJ

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q1 2024 Sales and Revenue Release

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : Q4 miss weighed heavily on the healthy 2024 guidance

February 01, 2024 at 07:42 am EST

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

225.1 CHF

Average target price

281.3 CHF

Spread / Average Target

+24.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-7.93%	199B
ELI LILLY AND COMPANY	+28.79%	676B
NOVO NORDISK A/S	+25.94%	559B
JOHNSON & JOHNSON	-5.84%	356B
MERCK & CO., INC.	+15.75%	320B
ABBVIE INC.	+4.32%	286B
ASTRAZENECA PLC	+4.00%	213B
NOVARTIS AG	+1.92%	207B
PFIZER, INC.	-10.00%	147B
AMGEN INC.	-7.82%	142B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals